[Metabolic rhabdomyolysis during statin therapy].
The occurrence of rhabdomyolysis during statin treatment for dyslipidemia is a well-known side effect. However, the differential diagnosis of rhabdomyolysis is large. We report on a patient treated with statin who presented a rhabdomyolysis. The persistence of laboratory abnormalities allowed to discover a metabolic rhabdomyolysis, namely a carnitine palmitoyltransférase II deficiency. The diagnosis of the genetic abnormality allows to modify the therapeutic care.
Vergely
N
N
Service d'endocrinologie, hôpital Bellevue, CHU de Saint-Etienne, 42027 Saint-Etienne, France. nathalie.vergely@chu-st-etienne.fr
Leca
V
V
Antoine
J-C
JC
Germain
N
N
Khalfallah
Y
Y
Estour
B
B
D000069059:Atorvastatin; D002334:Carnitine O-Palmitoyltransferase / Q000172:deficiency*; D006538:Heptanoic Acids / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D012206:Rhabdomyolysis / Q000175:diagnosis* / Q000235:genetics*
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D000069059:Atorvastatin; C086276:cerivastatin; D002334:Carnitine O-Palmitoyltransferase